ulevostinag   Click here for help

GtoPdb Ligand ID: 11972

Synonyms: compound 26 [PMID: 35332774] | MK-1454 | MK1454
Compound class: Synthetic organic
Comment: Ulevostinag (MK-1454) is a small molecule STING agonist that was developed as an anti-tumour agent [1]. It is a cyclic dinucleotide derivative.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 15
Hydrogen bond donors 3
Rotatable bonds 2
Topological polar surface area 345.95
Molecular weight 710.05
XLogP -0.81
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Nc1[nH]c(=O)c2c(n1)n(cn2)[C@@H]1O[C@H]2[C@H]([C@H]1O[P@](=O)(S)OC[C@@H]1[C@@H](O[P@@](=O)(OC2)S)[C@@H]([C@@H](O1)n1cnc2c1ncnc2N)F)F
Isomeric SMILES Nc1ncnc2c1ncn2[C@H]1[C@@H](F)[C@@H]2O[P@](=O)(S)OC[C@@H]3[C@H]([C@@H](O[P@@](=O)(OC[C@H]2O1)S)[C@@H](O3)n1c2nc(N)[nH]c(=O)c2nc1)F
InChI InChI=1S/C20H22F2N10O9P2S2/c21-8-6-1-36-42(34,44)40-12-7(39-18(9(12)22)31-4-27-10-14(23)25-3-26-15(10)31)2-37-43(35,45)41-13(8)19(38-6)32-5-28-11-16(32)29-20(24)30-17(11)33/h3-9,12-13,18-19H,1-2H2,(H,34,44)(H,35,45)(H2,23,25,26)(H3,24,29,30,33)/t6-,7-,8-,9+,12-,13-,18-,19-,42-,43-/m1/s1
InChI Key YSUIQYOGTINQIN-CLMXYZJCSA-N
No information available.
Summary of Clinical Use Click here for help
Intratumorally delivered ulevostinag is being evaluated in clinical trials in participants with advanced/metastatic solid tumours or lymphomas. The most advanced study is being conducted for head and neck squamous cell carcinoma (HNSCC).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03010176 Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) Phase 1 Interventional Merck Sharp & Dohme Corp.
NCT04220866 Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002) Phase 2 Interventional Merck Sharp & Dohme Corp.